Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer – a narrative review

INTRODUCTION: Radio-ligand targeted therapy is a new and promising concept of treatment Castration resistant prostate cancer (CRPC). Only a few radio-pharmaceutics were approved for usage in treating prostate cancer, among the multiple others tested. We aimed to review and summarize the literature o...

Descripción completa

Detalles Bibliográficos
Autores principales: Szponar, Paweł, Petrasz, Piotr, Brzeźniakiewicz-Janus, Katarzyna, Drewa, Tomasz, Zorga, Piotr, Adamowicz, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687416/
https://www.ncbi.nlm.nih.gov/pubmed/38033494
http://dx.doi.org/10.3389/fonc.2023.1239118
Descripción
Sumario:INTRODUCTION: Radio-ligand targeted therapy is a new and promising concept of treatment Castration resistant prostate cancer (CRPC). Only a few radio-pharmaceutics were approved for usage in treating prostate cancer, among the multiple others tested. We aimed to review and summarize the literature on the therapeutic isotopes specific for PSMA. METHODS: We performed a scoping literature review of PubMed from January 1996 to December 2022. RESULTS: 98 publications were selected for inclusion in this review. The studies contained in publications allowed to summarize the data on pharmacokinetics, therapeutic effects, side effects and the medical use of 225Ac and 177Lu radionuclides. The review also presents new research directions for specific PSMA radionuclides. CONCLUSION: Radioligand targeted therapy is a new and promising concept where Lu-177-PSMA-617 have promising outcomes in treatment according to standard of care.

Ejemplares similares